

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A bioadhesive pharmaceutical formulation comprising an active agent and a mucoadhesive carrier for the active agent, wherein the mucoadhesive carrier comprises a  $\beta$ -limit dextrin.
2. (Original) A bioadhesive pharmaceutical formulation as claimed in Claim 1 in which the  $\beta$ -limit dextrin is obtainable by hydrolysing starch with  $\beta$ -amylase.
3. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 in which the active agent is a pharmaceutically active agent.
4. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 which is a buccal-melt type product.
5. (Original) A bioadhesive pharmaceutical formulation as claimed in Claim 4 which is a wafer.
6. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 which is a powder for use in aerosol delivery formulations.
7. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 which is a thin film.
8. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 further including at least one carbohydrate.

9. (Original) A bioadhesive pharmaceutical formulation as claimed in Claim 8 in which the at least one carbohydrate is a polysaccharide.

10. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 8 in which the at least one carbohydrate is selected from the group consisting of alginate; pectin; and derivatives of alginate and pectin.

11. (Original) A bioadhesive pharmaceutical formulation as claimed in Claim 10 in which the alginate comprises between 1 and 50% of the formulation (w/w).

12. (Original) A bioadhesive pharmaceutical formulation as claimed in Claim 11 in which the alginate comprises between 10 and 30% of the formulation (w/w).

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 in a form selected from the group consisting of particulate; capsule; tablet; freeze dried matrix; wafer; liquid; and thin film.

17. (Original) A nutritional product comprising  $\beta$ -limit dextrin in which the  $\beta$ -limit dextrin is a main energy source in the product.

18. (Original) A nutritional product as claimed in Claim 17 which is an energy drink.

19. (previously presented) A nutritional product as claimed in Claim 17 which is a confectionery product.

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Previously presented) A bioadhesive pharmaceutical formulation as claimed in Claim 1 in which the  $\beta$ -limit dextrin is obtainable by hydrolysing starch.

24. (Canceled)

25. (Previously presented) A bioadhesive pharmaceutical formulation claimed in Claim 23 in which the starch is a waxy starch.

26. (Currently amended) A method for delivering an active agent to a mucosal membrane of a mammal comprising administering to said mammal a bioadhesive formulation comprising said active agent and a mucoadhesive carrier for the active agent, wherein the mucoadhesive carrier comprises a  $\beta$ -limit dextrin.

27. (Previously presented) A method according to Claim 26, wherein the active agent is a breath freshener.

28. (Previously presented) A method according to Claim 27, wherein the formulation is a thin-film breath freshener.

29. (Previously presented) A method according to Claim 26, wherein the active agent

is a pharmaceutically active agent.

30. (Previously presented) A method of providing nutrition to a subject comprising administering to the subject a nutritional product comprising a  $\beta$ -limit dextrin as an energy source.

31. (Previously presented) A method according to Claim 30, wherein the  $\beta$ -limit dextrin is the main energy source in the product

32. (Previously presented) A method according to Claim 30, wherein the  $\beta$ -limit dextrin is a slow release energy source.

33. (Previously presented) A method according to Claim 30, wherein the nutritional product is an energy drink.

34. (Previously presented) A method according to Claim 30, wherein the  $\beta$ -limit dextrin is obtainable by hydrolysing starch.

35. (Previously presented) A method according to Claim 34, wherein the  $\beta$ -limit dextrin is obtainable by hydrolysing starch with  $\beta$ -amylase.

36. (New) A bioadhesive pharmaceutical formulation according to claim 1, wherein said formulation is a lyophilized formulation.

37. (New) A method according to claim 26, wherein said formulation is a lyophilized formulation.